Open access
Open access
Powered by Google Translator Translator

Archives

Meta-analysis (mostly of observational studies): In patients undergoing pancreaticoduodenectomy, routine nasogastric decompression is associated with increased rates of delayed gastric emptying, major complications, and longer length of stay compared to no routine nasogastric decompression.

8 Jan, 2022 | 22:44h | UTC

Impact of routine nasogastric decompression versus no nasogastric decompression after pancreaticoduodenectomy on perioperative outcomes: meta-analysis – BJS Open

Related Study: Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial – JAMA Surgery

 

Commentary on Twitter

 


In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.

8 Jan, 2022 | 22:37h | UTC

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation – JAMA

Commentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD

Related:

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation – American Journal of Medicine

Observational Study Suggests Apixaban May Be a Better Choice than Rivaroxaban for Patients with Atrial Fibrillation

 


RCT: Postoperative radiotherapy (PORT) did not increase disease-free survival compared with no PORT in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement.

8 Jan, 2022 | 22:38h | UTC

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Postoperative Radiotherapy for Patients With Completely Resected Stage IIIA NSCLC and N2 Involvement – The ASCO Post

Post-Operative Radiotherapy Not Tied to Better Disease-Free Survival in NSCLC – MedPage Today (free registration required)

 


Happy Holidays! We will return with our activities on January 10, 2022. Any breakthrough articles during this break will be delivered at the beginning of the year.

20 Dec, 2021 | 10:28h | UTC


AAP Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic.

17 Dec, 2021 | 09:57h | UTC

Interim Guidance on Supporting the Emotional and Behavioral Health Needs of Children, Adolescents, and Families During the COVID-19 Pandemic – American Academy of Pediatrics

Commentary: AAP Issues Guidance for Children’s Emotional Needs During COVID-19 – HealthDay

 


Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.

8 Jan, 2022 | 22:36h | UTC

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Commentaries:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology

 


RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 


RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 


WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 


Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

17 Dec, 2021 | 09:54h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Commentaries:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)

 


CDC advisors recommend mRNA COVID vaccines over J&J.

17 Dec, 2021 | 09:46h | UTC

CDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP

 


Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.

17 Dec, 2021 | 09:48h | UTC

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

 

Commentary on Twitter

 


Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests.

17 Dec, 2021 | 09:47h | UTC

News Release: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University

Original Study: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA

 


NICE Guideline | Acute heart failure: diagnosis and management.

17 Dec, 2021 | 08:48h | UTC

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Related: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

 


Opinion: COVID-19 vaccine strategies must focus on severe disease and global equity.

17 Dec, 2021 | 09:45h | UTC

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

 


How COVID vaccines shaped 2021 in eight powerful charts.

17 Dec, 2021 | 09:44h | UTC

How COVID vaccines shaped 2021 in eight powerful charts – Nature

 


Consensus Statement: Treatment of combined injuries to the anterior cruciate ligament and the medial collateral ligament complex.

17 Dec, 2021 | 08:38h | UTC

Treatment of Combined Injuries to the ACL and the MCL Complex: A Consensus Statement of the Ligament Injury Committee of the German Knee Society (DKG) – Orthopaedic Journal of Sports Medicine

 


NICE Guideline | Type 2 diabetes in adults: management.

17 Dec, 2021 | 08:45h | UTC

Type 2 diabetes in adults: management – National Institute for Health and Care Excellence

Related: Guideline: ADA 2021 Standards of Medical Care in Diabetes

 


Guideline: Prevention, diagnosis, and management of post-surgical mediastinitis in adults.

17 Dec, 2021 | 08:41h | UTC

Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (SEICAV), the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) and the Biomedical Research Centre Network for Respiratory Diseases (CIBERES) – Journal of Clinical Medicine

 


NICE Guideline | Fever in under 5s: assessment and initial management.

17 Dec, 2021 | 08:44h | UTC

Fever in under 5s: assessment and initial management – National Institute for Health and Care Excellence

Related: AAP Guideline: Evaluation and management of well-appearing febrile infants 8 to 60 days old.

 


Prevention of Chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.

17 Dec, 2021 | 08:32h | UTC

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)

 


M-A: Adjuvant chemotherapy for muscle-invasive bladder cancer.

17 Dec, 2021 | 08:28h | UTC

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials – European Urology

 

Commentary on Twitter

 


Review uncovers weak COVID clinical practice guidelines.

16 Dec, 2021 | 10:31h | UTC

Review uncovers weak COVID clinical practice guidelines – CIDRAP

Original Study: Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 


Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 


Modeling COVID-19 mortality across 44 Countries: Face covering may reduce deaths.

16 Dec, 2021 | 10:33h | UTC

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths – American Journal of Preventive Medicine

Commentary: Mask laws could prevent unnecessary COVID-19 deaths, study shows – News Medical

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.